Table 1.
Summary of the studied effects and diseases, with the help of animal models.
| Animal Model | Studied Effect or Disease |
|---|---|
| Wistar rats [11,14,16,19] | insulin sensitizing effect, chemoprotective action, cardioprotective effect |
| Goto-Kakizaki rats [17] | insulin sensitizing effect, diabetes caused CV complications |
| Sprague–Dawley rats [40] | insulin sensitizing effect, the role of BGP-15 in alleviating ventilation-induced diaphragm dysfunction |
| Zucker obese rats [4] | insulin sensitizing effect in combination of rimonabant |
| CD-1 mice [1] | liver injury |
| Leptin deficient (ob/ob) mice [44] | testing the role of Hsp72 effective in the treatment of obesity-induced insulin resistance |
| mdx and dko mice [15,46] | Duchenne muscular dystrophy |
| hairless mice (VAF/plus CRL: hr/hr BR) [20] | photoprotective effect |
| BALB/c mice [48,49,50] | PCOS, oxaliplatin therapy induced skeletal myopathy and intestinal dysfunction |
| NMRI CV1 mice and BD2F1 mice [21] | cisplatin caused nephrotoxicity |
| Hsp110 deficient mice [22] | traumatic brain injury |
| CB6F1 mice [53] | effect of BGP-15 on the contractile function and morphology of regenerating soleus muscles |
| cardiac-specific dnPI3K-Mst1 Tg mice20 and cardiac-specific MURC Tg mice40 [18] | heart failure |
| mouse model of Alstrom syndrome [55] | mitochondrial dysfunction |
| C57BL/6 mice [56] | gestational diabetes mellitus |
| white New Zealand rabbits [14] | insulin sensitizing effect |
| Drosophila melanogaster [57] | tachycardia |